Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24837285 | 0.82 | HRH3 (0.36) | HRH3SMYD3KCNH2LMNAGAA | |
| SCHEMBL24008844 | 0.80 | NCF1 (0.42) | HRH3SMYD3 | |
| SCHEMBL8242487 | 0.78 | HRH3 (0.38) | HRH3SMYD3KCNH2LMNAGAA | |
| SCHEMBL10218778 | 0.77 | HRH3 (0.37) | HRH3SMYD3KCNH2LMNAGAA | |
| SCHEMBL20147689 | 0.75 | JAK2 (0.38) | HRH3SMYD3KCNH2LMNAGAA | |
| SCHEMBL178291 | 0.75 | HRH3 (0.43) | HRH3KCNH2 | |
| SCHEMBL24838550 | 0.72 | HRH3 (0.39) | HRH3KCNH2LMNAGAAF10 | |
| SCHEMBL24837396 | 0.72 | CYP2D6 (0.33) | HRH3KCNH2LMNAGAAF10 | |
| SCHEMBL24837283 | 0.71 | HTR4 (0.35) | HRH3KCNH2LMNAGAAF10 | |
| SCHEMBL23384367 | 0.69 | HRH3 (0.37) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | HRH3 4216/4885SMYD3 847/4885KCNH2 4285/4885 |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | ENPP1, ENPP3, SMPD1 | HRH3 4216/4885SMYD3 847/4885KCNH2 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.